NCT01532700 2019-09-24An Open-Label Phase 2 Study of Ofatumumab (Arzerra) in Combination With Oral GSK2110183 in the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)University Health Network, TorontoPhase 2 Completed28 enrolled 12 charts